Kush Parmar Sells 27,000 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Kush Parmar sold 27,000 shares of the firm's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total transaction of $202,500.00. Following the completion of the transaction, the director directly owned 1,093,313 shares of the company's stock, valued at $8,199,847.50. This represents a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Kush Parmar also recently made the following trade(s):

• On Friday, June 27th, Kush Parmar sold 75,000 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.91, for a total transaction of $518,250.00.
• On Monday, June 30th, Kush Parmar sold 25,000 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.81, for a total transaction of $170,250.00.

Entrada Therapeutics Stock Up 3.8%

Shares of NASDAQ TRDA traded up $0.25 during mid-day trading on Monday, reaching $6.80. 94,423 shares of the company were exchanged, compared to its average volume of 134,703. The company's 50-day simple moving average is $7.68 and its 200-day simple moving average is $10.21. The stock has a market capitalization of $258.08 million, a P/E ratio of 8.40 and a beta of -0.11. Entrada Therapeutics, Inc. has a twelve month low of $6.48 and a twelve month high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.36. Entrada Therapeutics had a net margin of 14.39% and a return on equity of 5.84%. The firm had revenue of $8.75 million for the quarter, compared to analysts' expectations of $10.98 million. As a group, equities research analysts expect that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Hedge Funds Weigh In On Entrada Therapeutics

Large investors have recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new stake in Entrada Therapeutics in the 4th quarter valued at $36,000. BNP Paribas Financial Markets bought a new stake in shares of Entrada Therapeutics in the fourth quarter valued at about $57,000. Virtus ETF Advisers LLC bought a new stake in shares of Entrada Therapeutics in the fourth quarter valued at about $68,000. AlphaQuest LLC acquired a new position in shares of Entrada Therapeutics in the fourth quarter valued at about $70,000. Finally, Russell Investments Group Ltd. increased its position in Entrada Therapeutics by 53,455.6% during the fourth quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock worth $83,000 after acquiring an additional 4,811 shares during the period. Institutional investors own 86.39% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on TRDA shares. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Tuesday, May 20th. Wall Street Zen raised Entrada Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, June 27th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $25.67.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.